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Summary Researchers worldwide with information about the Kirsten ras (Ki-ras) tumour genotype and outcome of patients with colorectal
cancer were invited to provide that data in a schematized format for inclusion in a collaborative database called RASCAL (The Kirsten ras in-
colorectal-cancer collaborative group). Our results from 2721 such patients have been presented previously and for the first time in any
common cancer, showed conclusively that different gene mutations have different impacts on outcome, even when the mutations occur at the
same site on the genome. To explore the effect of Ki-ras mutations at different stages of colorectal cancer, more patients were recruited to the
database, which was reanalysed when information on 4268 patients from 42 centres in 21 countries had been entered. After predetermined
exclusion criteria were applied, data on 3439 patients were entered into a multivariate analysis. This found that of the 12 possible mutations
on codons 12 and 13 of Kirsten ras, only one mutation on codon 12, glycine to valine, found in 8.6% of all patients, had a statistically
significant impact on failure-free survival (P = 0.004, HR 1.3) and overall survival (P = 0.008, HR 1.29). This mutation appeared to have a
greater impact on outcome in Dukes’ C cancers (failure-free survival, P = 0.008, HR 1.5; overall survival P = 0.02, HR 1.45) than in Dukes’ B
tumours (failure-free survival, P = 0.46, HR 1.12; overall survival P = 0.36, HR 1.15). Ki-ras mutations may occur early in the development of
pre-cancerous adenomas in the colon and rectum. However, this collaborative study suggests that not only is the presence of a codon 12
glycine to valine mutation important for cancer progression but also that it may predispose to more aggressive biological behaviour in patients
with advanced colorectal cancer. © 2001 Cancer Research Campaign http://www.bjcancer.com 
It is widely accepted that mutations in the Kirsten ras (Ki-ras) gene
in patients with colorectal cancer develop early in the progression
from adenoma to carcinoma. Our first collaborative study
including 2721 patients, clarified that Ki-ras mutations are not only
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important for the development of colorectal cancer but also for its
progression (Andreyev et al, 1998). We showed that the presence
of a mutation in Ki-ras increased risk of death by 26% (P = 0.004).
Secondly, for the first time in any common cancer, we conclu-
sively showed that different mutations may have different effects.
For example, any mutation of guanine (G) to thymidine (T) but not
to adenine (A) or to cytosine (C) increased the risk of death by
44% (P = 0.0002). When individual mutations were evaluated, one
single mutation found in just under 10% of all patients with
colorectal cancer – that of glycine to valine on codon 12 – was
an independent risk factor for recurrence (P = 0.0008) and death
(P = 0.0019). Thus, Ki-ras mutations were associated with an
increased risk of relapse and death, and some mutations were
found to be more aggressive than others. 
The size of our collaborative database also allowed definitive
conclusions to be drawn on a number of other unresolved issues.
In particular, we found that mutations were not associated with
gender, age, tumour site or Dukes’ stage and that mutation rates
seen in patients with sporadic tumours were comparable to the
rates observed in patients with a predisposing cause for their
cancer. 
One intriguing possibility arising from our first study was that
the aggressive mutations were playing a different role in early
tumours compared to more advanced tumours. However, the first
RASCAL (The Kirsten ras in-colorectal-cancer collaborative
group) study was too small to define this point and it became
obvious that additional patients would need to be recruited to the
database so that this second study could explore further the role of
the Ki-ras mutation at different stages of colorectal cancer. 
METHODS 
Patients 
At least 2 invitations were sent to all researchers who had
published original data in English or were known to have unpub-
lished data on the significance of the Ki-ras gene in patients with
colorectal adenocarcinoma. They were invited to participate in a
collaborative register collecting original clinical data from such
patients. 
Participants were required to complete a questionnaire for each
patient and details were entered into a database. All collaborators
were asked to ensure that information in 3 areas in particular was
as complete as possible. The following information was requested:
(1) the genotype of the Ki-ras gene in the primary tumour at
codons 12 and 13, (2) the date, Dukes’ stage and apparent imme-
diate outcome of any surgery for that cancer and (3) dates of
follow-up and long-term outcome. Specific causes of death and
dates of recurrence, if relevant, were also sought. All data were
coded so that patient identity was only known to their physicians
and were entered by one statistician (ARN) into a database called
RASCAL. 
Statistics 
Survival curves were generated using the product-limit method of
Kaplan–Meier. The log rank test was used to evaluate differences
in failure-free survival and overall survival curves. Failure-free
survival was defined as the time from operation to relapse or death
from any cause apart from peri-operative deaths. Overall survival
was defined as the time from operation to death from any cause.
Chi-square tests were used for comparison of categorical data. In
view of the multiple statistical analyses performed and the large
number of patients, only values where P < 0.01 were considered
significant. Multivariate analysis was performed using Cox’s
model for proportional hazards survival analysis. Hazard ratios
(HRs) and 95% confidence intervals (CIs) of the hazard ratios
were calculated from the individual Cox multivariate analyses. All
P-values were calculated from the improvement in log likelihood
and were expressed as two-sided. 
Bias introduced by the findings of different centres was exam-
ined using the test for heterogeneity across centres. The difference
in prevalence of mutations between centres was examined using a
chi-square test. Centre was treated as a random effect and age
treated as a continuous variable in the model. Dukes’ stage was
analysed using dummy variables for each stage relative to Dukes’
A. A separate model was generated for each of the mutation types.
This allowed a hazard ratio to be calculated for each type sepa-
rately, after controlling for centre, age and Dukes’ stage. The
model was repeated for the Dukes’ B and then Duke’s C patients
separately to get an estimate of the effect on the individual stages. 
RESULTS 
Patient selection 
Data on 4268 patients from 42 different centres in 21 countries
were entered onto the RASCAL database (Table 1). Our earlier
study had previously reported on 2721 of these in whom there had
been clinical outcome data in 2445. 
Patients excluded from further analysis were those with
missing age (n = 203) or Dukes’ stage (n = 75). Perioperative
deaths (n = 76) are all included in the database but the deaths are
censored and do not count as events. Data from one centre (n = 34)
were removed as patient autopsy specimens were used. Centres
that did not provide information about the exact mutation type
were also excluded (n = 488). Where a centre had a minority of
missing mutation types, only the missing mutation patients were
removed. Patients were also excluded if information provided for
codon 12 included only mutations and data on codon 13 was
missing (n = 49 from 9 centres excluding 1.3–34.3% of their data).
After these exclusions, the number of patients used for the analysis
Table 1 Characteristics of 4268 patients from 42 different centres in 21
countries enrolled in the RASCAL database 
Characteristic Male Female Unknown Total 
No. of patients 2263 1977 28 4268 
Median age in years (range) 68 (17–95) 68 (19–103) ––
Dukes’ stage 
A 334 304 5 643 
B 941 819 9 1769 
C 659 589 8 1256 
D 287 238 0 525 
Unknown 42 27 6 75 
Alive at last follow up 1228 1137 26 2391 
Cause of death 
Peri-operative 48 28 0 76 
Cancer 600 559 1 1160 
Unrelated to cancer 191 116 0 307 
Unknown 196 137 1 334 
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Bias introduced by the findings of different centres seemed to be
of little significance as the test for heterogeneity across centres
evaluated to P = 0.22, indicating that the data did not statistically
differ between centres. However, when the prevalence of muta-
tions between centres was examined, a value of P < 0.001 was
obtained, suggesting a significant association between centre and
mutation rate, perhaps because some centres used more sensitive
techniques than others to detect mutations. 
Results of multivariate analysis 
The age of the patient was a highly significant factor in our model.
Even so, age barely influences the hazard ratios finally generated,
as the estimations of mutation effects hardly differed whether age
was or was not included. 
We analysed the effects of a valine mutation in 2 different ways.
First, we compared it to other mutations or wild type (no mutation)
after controlling for Dukes’ stage, age and centre (Table 3). 
A valine mutation reduced both failure-free (P = 0.004, HR 1.3,
95% CI 1.09–1.54) and overall survival (P = 0.008, HR 1.23, 95%
CI 1.08–1.54). These data fall well within the CIs calculated from
the smaller sample published in the 1st RASCAL study, where
each centre was treated as a fixed effect rather than a random effect
as used here. In addition, we again found that when guanine
nucleotides were mutated to thymidine (but not adenine or cyto-
sine) this also conveyed an adverse outcome on failure-free (P =
0.002, HR 1.27, 95% CI 1.1–1.47) and overall survival (P = 0.002,
HR 1.28, 95% CI 1.1–1.5). 
A second way to look at the same data was to compare the effect
of all mutations together compared to wild type (Table 4). This
puts all factors in at the same time and controls for them all. This
model again found that only Dukes’ stage, age and a valine muta-
tion to be statistically significant independent risk factors for
overall survival (P = 0.008, HR 1.29, 95% CI 1.08–1.55). The risk
conveyed by the presence of a valine mutation in the data from
individual centres is shown in Figure 1. 
When the effects of a valine mutation on the Dukes’ B (Table 5)
and Dukes’ C patients (Table 6) were analysed separately, we
observed that the presence of a valine mutation in patients with
Dukes’ C carcinoma reduced the failure-free survival rate signifi-
cantly (P = 0.0076, HR 1.5, 95% CI 1.13–1.98) and with a trend
toward statistical significance when overall survival was consid-
ered (P = 0.02, HR 1.45, 95% CI 1.07–1.96). In contrast, the pres-
ence of a valine mutation had no effect on failure-free survival 
(P = 0.46, HR 1.12, 95% CI 0.84–1.46 and overall survival 
(P = 0.36, HR 1.15, 95% CI 0.86–1.53) in patients with Dukes’
B carcinoma. 
DISCUSSION 
This second RASCAL study is by far the largest study to date
examining the impact of a mutation in the Ki-ras gene on the
outcome of patients with colorectal cancer. Although two-thirds of
694 J Andreyev et al 
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Table 2 Characteristics of 3439 patients from 35 centres in 19 countries
included in the multivariate analysis 
Characteristic Male Female Unknown Total 
No. of patients 1824 1611 4 3439 
Median age in years (range) 67 (17–95) 69 (19–103) ––
Dukes’ stage 
A 276 270 2 548 
B 752 645 2 1399 
C 558 498 0 1056 
D 238 198 0 436 
Alive at last follow up 984 923 4 1911 
Cause of death 
Peri-operative 44 22 0 66 
Cancer 484 449 0 933 
Unrelated to cancer 138 90 0 228 
Unknown 174 127 0 301 
Table 3 The 2nd RASCAL study: results of the 1st multivariate analysis including failure-free and overall survival 
Total Failure-free survival Overall survival 
Factor n = n = relapse or death P-value Hazard ratio 95 % CI n = deaths P-value Hazard ratio 95 % CIs 
Dukes’ stage 
A 548 148 1 129 1 
B 1399 545 < 0.0001 1.54 1.29–1.85 485 < 0.0001 1.63 1.34–1.98 
C 1056 610 < 0.0001 3.42 2.85–4.09 540 < 0.0001 3.37 2.78–4.09 
D 436 291 < 0.0001 9.74 7.95–11.93 274 < 0.0001 11.65 9.40–14.44 
Age 3439 1594 < 0.0001 1.01 1.008–1.02 1428 < 0.0001 1.02 1.01–1.02 
Hospital 3439 1594 < 0.0001 0.99 0.988–1.00 1428 0.0005 0.99 0.99–1.00 
Codon 12 mutations 
Valine 300 148 0.004 1.30 1.09–1.54 129 0.008 1.29 1.08–1.55 
Aspartate 354 171 0.613 1.04 0.89–1.22 143 0.441 0.94 0.79–1.11 
Cysteine 92 54 0.447 1.11 0.85–1.46 51 0.169 1.26 0.93–1.62 
Serine 75 42 0.035 1.42 1.04–1.93 34 0.300 1.20 0.86–1.70 
Alanine 79 41 0.237 1.21 0.89–1.66 38 0.082 1.35 0.98–1.87 
Codon 13 mutations 
Aspartate 297 149 0.469 0.94 0.79–1.12 139 0.437 0.93 0.78–1.12 
Mutation type 
Guanine to thymidine 409 208 0.002 1.27 1.10–1.47 187 0.002 1.28 1.10–1.50 
Guanine to cytosine 114 55 0.229 1.19 0.90–1.56 52 0.051 1.33 1.01–1.76 
Guanine to adenine 713 355 0.381 1.06 0.94–1.19 309 0.626 0.97 0.85–1.10 
This analysis compared the presence of a valine mutation to all other mutations or wild type after controlling for Dukes’ stage, age and centre. 
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second study confirms that a glycine to valine mutation on codon
12 of the Ki-ras gene has a significant association with biological
behaviour in colorectal cancer. The purpose of this second study
was to explore the role of mutations at different stages of
colorectal cancer and our findings suggest that this mutation is
particularly aggressive in patients with Dukes’ C cancer, in whom
it is associated with a 50% increased risk of relapse or death. 
We were unable to show a similar association between the pres-
ence of a valine mutation and outcome in patients with Dukes’ B
cancers. The explanation for this may be that there is no associa-
tion between outcome and Ki-ras mutations in these patients.
However, if abnormalities in the Ki-ras gene are important for the
development of adenomas within the bowel, (Vogelstein et al,
1988), it is difficult to explain how they could be unimportant in
less advanced cancers (Dukes’ B) but still have a role in deter-
mining prognosis in more advanced cancers (Dukes’ C). So, a
second explanation for our lack of an association in Dukes’ B
tumours, is that despite the size of our colorectal cancer cohort,
4268 patients, our study was still significantly underpowered and a
real difference has not been detected. Equally, our finding for the
Dukes’ C cancers may be a type 1 error, where a difference has
been detected when none really exists. 
When all valine mutations were examined together, our study
approximately evaluates to 90% power to see a true effect.
However, when the Dukes’ C group tumours were considered, to
2nd RASCAL collaborative study 695
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Table 4 2nd RASCAL study: results of the 2nd multivariate analysis: overall
survival. The effects of all mutations together compared to wild type. All
factors are included simultaneously and the model controls for them all 
Total Overall survival 
Factor n = n = deaths P-value Hazard ratio 95% CIs 
Dukes’ stage 
A 548 129 – 1 – 
B 1399 485 <0.0001 1.633 1.34–1.98 
C 1056 540 <0.0001 3.09 2.59–3.75 
D 436 274 <0.0001 11.65 9.4–14.44 
Age 3439 1428 <0.0001 1.018 1.01–1.02 
Hospital 3439 1428 0.0005 0.993 0.99–1.00 
Codon 12 mutations 
Valine 300 129 0.008 1.29 1.08–1.55 
Aspartate 354 143 0.594 ––  
Cysteine 92 51 0.134 ––  
Serine 75 34 0.253 ––  
Alanine 79 38 0.064 ––  
Codon 13 mutations 
Aspartate 297 139 0.585 0.585 – 
Table 5 2nd RASCAL study: results of the multivariate analysis when the effects of a valine mutation on the Dukes’ B patients were analysed separately
Total Failure-free survival Overall survival 
n = n = relapse or death P-value Hazard ratio 95% CIs n = deaths P-value Hazard ratio 95% CIs
Dukes’ stage B 1399 545 485 
Codon 12 mutations 
Valine 138 57 0.46 1.11 0.84–1.46 52 0.36 1.15 0.86–1.53 
Aspartate 137 54 0.53 1.10 0.83–1.45 48 0.71 1.06 0.78–1.43 
Cysteine 24 15 0.10 1.59 0.95–2.66 14 0.14 1.53 0.90–2.61 
Serine 29 15 0.19 1.44 0.86–2.41 11 0.68 1.14 0.63–2.07 
Alanine 28 10 0.55 1.22 0.65–2.28 8 0.66 1.18 0.58–2.37 
Codon 13 mutations 
Aspartate 130 48 0.02 0.70 0.51–0.96 45 0.06 0.74 0.54–1.02 
Mutation type 
Guanine to thymidine 168 74 0.08 1.25 0.98–1.59 69 0.11 1.24 0.96–1.60 
Guanine to cytosine 44 16 0.30 1.30 0.80–2.12 15 0.25 1.37 0.82–2.30 
Guanine to adenine 278 113 0.54 0.94 0.76–1.15 96 0.39 0.91 0.73–1.13 
Table 6 The 2nd RASCAL study: results of the multivariate analysis, when the effects of a valine mutation on Dukes’ C patients were analysed separately 
Total Failure-free survival Overall survival 
n = n = relapse or death P-value Hazard ratio 95% CIs n = deaths P-value Hazard ratio 95% CIs
Dukes’ stage C 1056 610 540 
Codon 12 mutations 
Valine 84 54 0.008 1.13–1.98 46 0.02 1.45 1.07–1.96 
Aspartate 121 70 0.85 1.02 0.80–1.31 54 0.15 0.82 0.62–1.08 
Cysteine 29 17 0.43 0.83 0.5 – 1.34 15 0.52 0.85 0.51–1.42 
Serine 22 15 0.04 1.83 1.09–3.06 13 0.08 1.72 0.99–2.99 
Alanine 20 12 0.82 1.07 0.60–1.90 11 0.72 1.12 0.61–2.03 
Codon 13 mutations 
Aspartate 81 58 0.78 0.96 0.73–1.27 45 0.81 0.97 0.73–1.29 
Mutation type 
Guanine to thymidine 119 70 0.10 1.24 0.97–1.58 63 0.13 1.23 0.95–1.60 
Guanine to cytosine 28 16 0.79 1.07 0.66–1.73 16 0.62 1.14 0.69–1.87 
Guanine to adenine 225 139 0.52 1.07 0.88–1.29 114 0.51 0.93 0.76–1.15 
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detect a change in survival at 5 years from 40–50% with 90%
power in patients with a valine mutation, compared to those with
wild type or one of the other mutations, 1800 ‘events’ (relapses or
deaths) would have had to occur in the Dukes’ C patients. We had
610 events. To detect a similar 10% improvement in 5-year
survival in the Dukes’ B patients (from 60% to 70%) with 90%
power, we needed 1045 events, while we had only 545. 
Nevertheless, we have demonstrated that when researchers are
willing to share original data to answer very specific issues – even
data on individual patients – this gives studies great power that
cannot be matched by individual groups. For example, the largest
number of patients provided by any one author for this study was
283, so the only way to answer questions about the relationship
between prognosis and individual mutations is through collabora-
tion. The RASCAL studies also emphasize that it is no longer
adequate to look for the presence or absence of mutations in
tumours, but that instead research must concentrate on the indi-
vidual mutations that are present. Up to 1 million people develop
colorectal cancer annually worldwide. Of these, 86 000 have a
valine mutation. This clinical study therefore, together with
laboratory evidence, provides a real rationale for developing
therapeutic strategies targeting this mutation. 
Our findings from this clinical study support sound experi-
mental evidence, reviewed in Al-Mulla et al (1999), that valine
mutations produce proteins that behave differently to other
mutated Ki-ras proteins. Different mutations within codon 12 lead
to variation in the biological activity of mutated Ki-ras proteins by
reducing GTPase activity and affinity for GTPase-activating
proteins, preventing activation of GTPase-activating proteins and
altering Ki-ras protein dissociation from binding proteins or down-
stream effectors. These critical molecular changes probably occur
because of structural differences induced by mutations, particu-
larly when the mutated Ki-ras protein is in its GTP-bound state. 
In conclusion, this collaborative project has shown that a specific
mutation in the Ki-ras gene at codon 12, found in 8.6% of all
patients with colorectal cancer, increases the risks of recurrence or
death by 30%. The presence of this mutation in Dukes’ C tumours
is associated with a higher risk of recurrence or death, 50%. 
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Figure 1 Survival hazard ratios from data provided by the group
collaborating in the RASCAL study, if a valine mutation is present. The box
shows the relative size of the cohort from each centre; its position on the
chart represents the degree of hazard conveyed by the presence of a valine
mutation in the cohort from each centre providing survival data. The arms on
either side of the box indicate the 95% CIs. Where no events occurred, or the
centre reported no valine mutations, or the mutation types were not specified
among the patients from a centre, no box is shown on this diagram. The
number of patients included in the analysis/total number supplied by that
centre is shown in brackets after the name of the centre 
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